Taken together, this indicates that induction of serum NGF arises from MM interaction with the bone microenvironment, and that novel treatments targeted towards MM will benefit by targeting either the inflammatory signalling induced by MM, or the downstream effectors such as NGF. The gene discussed is NGF; the disease is Miyoshi myopathy.